#Immunotherapy #Switzerland #Zurich #Fapon Biopharma #CD3 TCE

Fapon Biopharma's Breakthrough at the European Life Sciences CEO Forum

Fapon Biopharma, a leader in the biotech industry, made a significant announcement at the 19th Annual European Life Sciences CEO Forum, held at the Hilton Zurich Airport Hotel on March 4th and 5th. Dr. Kaiqing Zhang, the Associate Director of Business and Corporate Development at Fapon, presented the company's innovative CD3/TCR VHH T-cell engager (TCE) platform, which promises to revolutionize immunotherapy.

An Innovative Solution

In his presentation titled "Unlocking the Next Generation of TCEs: Fapon's Human/Cyno Cross-Reactive CD3/TCR VHH Platform," Dr. Zhang elaborated on how this proprietary platform is designed to address the challenges faced with traditional multispecific antibodies. These challenges often include limitations in development capabilities and flexibility.

Fapon's platform utilizes cross-reactive single-domain antibodies (VHH) derived entirely from humans and cynomolgus monkeys, enabling a unique modular "plug-and-play" design. This modularity is paired with optimized activation kinetics and a widened therapeutic index, positioning Fapon's technology at the forefront of upcoming therapeutics.

Targeting Major Health Issues

The CD3/TCR VHH TCE platform is poised to advance treatment in two rapidly growing sectors:
1. Oncology: The platform will facilitate precise T-cell redirection to effectively eradicate solid and hematologic tumors while minimizing excessive cytokine release risks through optimized activation kinetics and a broader therapeutic index.
2. Autoimmune Diseases: The TCE technology is being developed to create effective T-cell engagers aimed at achieving deep depletion of B-cells, thus offering a profound "immunologic reset" for patients suffering from refractory autoimmune conditions.

Safety and Efficacy

A cornerstone of Fapon's technology is its range of cross-reactive CD3/TCR VHHs, which exhibit varying binding affinities for both human and cynomolgus models. This dual reactivity significantly lowers the preclinical safety risks while expediting the translation timeline for clinical applications.

Preliminary evaluations of the platform have already yielded superior efficacy and safety profiles, with predictably advantageous pharmacokinetics and pharmacodynamics demonstrated in mouse and non-human primate studies.

Strategic Partnerships

Fapon Biopharma's capabilities extend beyond their innovative platform, boasting an exceptional chemistry, manufacturing, and controls (CMC) profile alongside flexibility in formulating multivalent products. The company is actively seeking strategic partners for collaborative development and licensing opportunities. Inquiries regarding partnership can be directed to Fapon through their designated channels for regions, including the USA, Europe, and Asia-Pacific.

About Fapon Biopharma

Fapon Biopharma specializes in discovering and developing biologics aimed at treating cancer, autoimmune diseases, and other medical conditions that require urgent attention. Utilizing cutting-edge technologies, the company has established advanced drug discovery platforms. Their pipeline includes a shear antibody discovery platform built on leading mammalian display technology, IL-10M-fusion protein production platforms, and a CD3-VHH based TCE platform.

Fapon remains committed to innovation, striving to develop safer, more effective, affordable biologics accessible to all.